Hypercholesterolemia Clinical Trial
Official title:
A Patient-Spouse Intervention for Self-Managing High Cholesterol
We examined the effect of a patient-spouse intervention to lower LDL-C by increasing patient treatment adherence. A randomized controlled trial compared a one-year, telephone-based patient-spouse intervention to usual care. The primary outcome was LDL-C measured three times (baseline, 6 months, 11 months); secondary outcomes were adherence to medication, diet, and exercise, also assessed at baseline, 6 months, and 11 months.
Background: Background/Rationale: Coronary heart disease (CHD) is the leading cause of death
in the United States, resulting in more than 500,000 heart attacks and another 500,00 deaths
per year. More than 80% of veterans have > 2 risk factors for CHD, underscoring the need for
intervention. One major modifiable risk factor for CHD is elevated low-density lipoprotein
cholesterol (LDL-C). Despite the proven success of diet, exercise, and medication, LDL-C
frequently is not at the optimum level, due in part to patient nonadherence. Therefore,
interventions are needed to increase adherence, thereby lowering LDL-C.
Objectives: Objectives: We examined the effect of a patient-spouse intervention to lower
LDL-C by increasing patient treatment adherence. The primary hypothesis was that patients
enrolled in a telephone-based, spouse-assisted intervention will experience a clinically
meaningful 7% reduction in LDL-C. The secondary hypotheses were that patients who receive
the intervention would show a significant increase in adherence to medication, diet, and
exercise.
Methods: In a 3-year study, a randomized controlled trial compared a 10-month,
telephone-based, spouse-assisted intervention to usual care. Married patients with
above-goal LDL-C and their spouses were consented, completed a baseline assessment, and then
were randomly assigned to the intervention or usual care arm. Month 1 involved an
educational call delivered to patients and spouses. Months 2-10 (except month 6) involved
monthly goal setting calls delivered to patients and calls focused on increasing social
support to spouses. The patient phone call will always preceded the spouse phone call. At 6
and 11 months, LDL-C and adherence were re-assessed. The primary outcome was LDL-C measured
three times (baseline, 6 months, 11 months); secondary outcomes were adherence to
medication, diet, and exercise, also assessed at baseline, 6 months, and 11 months.
Descriptive statistics were computed for all study variables within each study arm. Mixed
effects models were used to evaluate the intervention's effect on the primary and secondary
outcomes at 11 months. We also calculated intervention cost.
Status: Enrollment began in Fall, 2007 and was completed in July of 2009.
Impact: Elevated LDL-C is a major risk factor for CHD, stroke, and peripheral vascular
disease, all of which are common among veterans. The expected increase in prevalence of CHD
over the next several decades will result in an increased burden for both veterans and the
VA health care system. Despite the known risk of hypercholesterolemia, many veterans have
suboptimal LDL-C levels. As the latest evidence and recommendations suggest that these goals
should be even lower, interventions to assist patients to lower LDL-C increasingly will be
needed. The VA considers the reduction of LDL-C an important goal, as indicated by the major
effort of the Ischemic Heart Disease Quality Enhancement Research Initiatives (QUERI). This
study is important because (1) it addresses a highly prevalent risk factor for CHD among
veterans; (2) it proposes a potentially low-cost method for improving LDL-C levels, which in
turn could reduce VA healthcare costs; (3) the intervention is practical and could be
disseminated easily in the VA healthcare system if proven effective; and (4) this
intervention provides a model for self-management of other chronic diseases, such as
diabetes and hypertension.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
| Recruiting |
NCT03947866 -
Ezetimibe-Rosuvastatin Evaluation Study
|
||
| Completed |
NCT01709513 -
Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)
|
Phase 3 | |
| Completed |
NCT01212900 -
Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression
|
Phase 4 | |
| Completed |
NCT00001154 -
Lipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins
|
||
| Completed |
NCT02550288 -
A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-383)
|
Phase 3 | |
| Completed |
NCT03929198 -
Translation of Pritikin Program to the Community
|
N/A | |
| Completed |
NCT04485793 -
Effect of a Dietary Supplement on Lipid Pattern and Liver Parameters in Hypercholesterolemia
|
N/A | |
| Completed |
NCT02341924 -
Validating the "Foods for Health" Portfolio of Functional Food Products
|
N/A | |
| Active, not recruiting |
NCT02223793 -
Vascular Lifestyle-Intervention and Screening in Pharmacy
|
N/A | |
| Completed |
NCT01934608 -
The Effect of Synching Prescription Refills on Adherence
|
N/A | |
| Completed |
NCT01941836 -
Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients
|
Phase 2 | |
| Recruiting |
NCT01705873 -
Analysis on the Risk of Cardiovascular Events in HIV- Infected Subjects Treated With LPV/r Based HAART Regimen vs. an EFV Based Regimen
|
N/A | |
| Completed |
NCT01678521 -
Effect of LDL-apheresis on PTX3 Plasma Levels in Hypercholesterolemic Patients
|
N/A | |
| Completed |
NCT01670734 -
Pharmacokinetic and Tolerability of Alirocumab SAR236553 (REGN727) in Patients With Hepatic Impairment and in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT01370603 -
A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/40 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 40 mg Tablets in Participants With High Cholesterol (MK-0653C-190 AM1)
|
Phase 3 | |
| Completed |
NCT01370590 -
A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/20 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 20 mg Tablets in Participants With High Cholesterol (MK-0653C-185 AM1)
|
Phase 3 | |
| Completed |
NCT01575171 -
Using Nudges to Implement Comparative Effectiveness
|
N/A | |
| Completed |
NCT01446679 -
Special Drug Use-Results Survey of Lipitor Tablets
|
N/A | |
| Completed |
NCT01768403 -
Centralised Pan-Algerian Survey on the Undertreatment of Hypercholesterolemia
|
N/A |